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More than 130 different mutations in the gap junction integral plasma membrane protein connexin32 (Cx32) have been linked to the human peripheral neuropathy X-linked Charcot–Marie–
Tooth disease (CMTX). How these various mutants are processed by the cell and the mechanism(s) by which they cause CMTX are unknown. To address these issues, we have studied the
intracellular transport, assembly, and degradation of three CMTX-linked Cx32 mutants stably
expressed in PC12 cells. Each mutant had a distinct fate: E208K Cx32 appeared to be retained in
the endoplasmic reticulum (ER), whereas both the E186K and R142W mutants were transported
to perinuclear compartments from which they trafficked either to lysosomes (R142W Cx32) or
back to the ER (E186K Cx32). Despite these differences, each mutant was soluble in nonionic
detergent but unable to assemble into homomeric connexons. Degradation of both mutant and
wild-type connexins was rapid (t1/2 ⬍ 3 h) and took place at least in part in the ER by a process
sensitive to proteasome inhibitors. The mutants studied are therefore unlikely to cause disease by
accumulating in degradation-resistant aggregates but instead are efficiently cleared from the cell
by quality control processes that prevent abnormal connexin molecules from traversing the
secretory pathway.

INTRODUCTION
Charcot–Marie–Tooth (CMT) 1 disease is the name given to
a heterogeneous group of dominant disorders that collectively are the most common form of inheritable disease in
the peripheral nervous system (Murakami et al., 1996). The
X-linked form of CMT 1 disease (CMTX) is a progressive
demyelinating neuropathy characterized clinically by moderately reduced nerve conductance velocities. Manifestations of CMTX typically include weakness and atrophy of
the distal limb muscles, sensory loss in feet, lower legs, and
hands, pes cavus deformity, and decreased or absent deep
tendon reflexes (reviewed by Bone et al., 1997). The severity
of symptoms varies considerably between affected families
and in males ranges from mild impairment to being wheel‡
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chair-bound by age 50 y (Ionasescu et al., 1996; Deschenes et
al., 1997).
In 1993, CMTX was genetically linked to defects in the
gene encoding the tetra-spanning integral plasma membrane protein connexin32 (Cx32) (Bergoffen et al., 1993).
Cx32, like other members of the connexin protein family,
forms gap junctions in vertebrate tissues. Gap junctions are
collections of transmembrane channels that serve as lowresistance pathways for the diffusion of substances ⬍1 kDa
in molecular mass including ions, metabolites, and second
messengers (Goodenough et al., 1996). Usually, gap junctions form between two neighboring cells, creating intercellular conduits that relay messages between, and maintain
metabolic continuity within, connected cells. In contrast,
uninjured myelinating Schwann cells do not make gap junctions with each other or with neuronal cells. Instead, Cx32
appears to form gap junctions between adjoining wraps of
myelin within the sheath of a single Schwann cell at the
incisures of Schmidt–Lanterman and the paranodal region.
This creates a radial pathway for the diffusion of substances
that has been estimated to be up to 1000 times shorter than
the circumferential route (Scherer et al., 1995; Balice-Gordon
et al., 1998). Although the function of these intracellular gap
junctions is unclear, possibilities include dissipation of potassium gradients generated by neuronal activity and trans1933
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myelin transport of small trophic and signaling molecules.
Mice with a targeted deletion of the Cx32 gene, although
normal when young, gradually develop a progressive demyelinating neuropathy with histological features similar to
those observed in human CMTX patients (Anzini et al., 1997;
Scherer et al., 1998).
More than 130 different mutations in Cx32 have been
identified in CMTX patients (Bone et al., 1997). Essential to
elucidating the molecular mechanisms underlying CMTX
and the basis for genotype and phenotype correlations is
determining how defects in the Cx32 gene disrupt connexin
function. The great majority of CMTX-linked Cx32 mutations result in changes in single amino acid residues that
could affect channel formation, activity, and/or metabolic
stability. As determined from structural and biochemical
analysis, the first step in gap junction formation is the noncovalent oligomerization of six connexin monomers into a
hexameric annular structure known as a connexon. After
transport to the cell surface, two connexons on apposing
plasma membranes dock to form what is usually an intercellular channel, but which in Schwann cells instead links
adjacent myelin wraps. Last, these channels pack at up to
10,000/m2 into paracrystallin arrays known as gap junctional plaques (reviewed by Musil, 1994). Despite this complex assembly process, there is no evidence that gap junction
formation requires any nonconnexin protein(s). Another remarkable aspect of gap junctions is the rapid turnover rate of
connexins, which are degraded in a wide variety of cultured
and in vivo systems with a t1/2 of only 1.5–5 h even after
incorporation into gap junctional plaques (Fallon and Goodenough, 1981; Musil et al., 1990; Beardslee et al., 1998).
To date, it has not been possible to maintain either endogenous or exogenous Cx32 protein expression in cultured
Schwann cells (Scherer et al., 1995; Yoshimura et al., 1998),
necessitating the use of other systems for the in vitro study
of CMTX-linked Cx32 mutants. When transfected into otherwise connexin-deficient PC12 cells, several Cx32 point mutants, including R142W, E186K, and E208K, showed no detectable staining on the plasma membrane but instead
appeared to be defective in intracellular transport (Deschenes et al., 1997). The R142W Cx32 mutant also accumulated intracellularly when expressed under the control of the
myelin-specific Po promotor in the Schwann cells of either
Cx32 knock-out or otherwise normal mice (Bone et al., 1997;
Scherer et al., 1999). Both R142W/⫺ and R142W/⫹ mice
showed age-dependent demyelination and remyelination of
peripheral nerve. In R142W/⫹ animals, endogenous Cx32
was no longer detectable in the myelin sheath but instead
was localized to the same intracellular compartments as the
R142W Cx32 mutant. Dominant-negative activity of intracellularly retained CMTX-linked Cx32 mutants has also been
reported by Omori et al. (1996) in HeLa cell transfectants.
Taken together, these observations illustrate the potential for
certain CMTX-linked Cx32 mutants to have gain-of-function
effects and indicate that transfected PC12 cells are a suitable
system to study mutant trafficking.
Mutations in plasma membrane or secreted proteins that
inhibit transport to the cell surface can cause disease by one
of two general mechanisms (Kim and Arvan, 1998; Aridor
and Balch, 1999). Aridor and Balch (1999) have defined class
I mutations as those that prevent transport of the affected
protein to the plasma membrane but do not interfere with its
1934

ability to be efficiently degraded. Disease results from the
absence of the wild-type protein, and any proteins associated with it, from the cell surface. In contrast, class II mutations inhibit the turnover as well as the intracellular transport of the affected protein. Accumulation of undegraded
protein can then induce chronic endoplasmic reticulum (ER)
stress responses, which in turn may lead to major changes in
cell physiology such as apoptosis, abnormal differentiation,
and altered proliferation. A class II-type mechanism has
been proposed for mutants of proteolipid protein that cause
Pelizaeus–Merzbacher disease (Gow and Lazzarini, 1996;
Gow et al., 1998) and of peripheral myelin protein 22 that
result in CMT type 1A (D’Urso et al., 1998; Aridor and Balch,
1999). By analogy, toxic accumulation of Cx32 (also a tetraspanning integral plasma membrane protein of myelin) has
been suggested as a mechanism for some CMTX-linked
Cx32 mutants (Deschenes et al., 1997), although this contention has not been experimentally addressed.
One possibility consistent with the phenotypic variation
observed in CMTX patients is that different defects in Cx32
lead to distinct transport, assembly, and degradative fates.
That differences in intracellular processing can be associated
with separate disease mechanisms is illustrated by the finding that mutants of the water channel aquaporin-2 that are
restricted to the ER are linked with recessive nephrogenic
diabetes insipidus, whereas those that are arrested in the
Golgi cause a dominant form of the disease, apparently
because of formation of mixed oligomers with wild-type
aquaporin-2 (Kamsteeg et al., 1999). Given the aforementioned deleterious effects of intracellular accumulation of
undegraded mutant proteins, it is particularly important to
delineate the pathways by which mutant and wild-type
connexins are turned over. The lysosome has generally been
considered the major means of proteolysis of membraneassociated proteins and has been shown to participate in the
turnover of gap junctional plaques (Larsen and Tung, 1978).
Recent evidence has, however, indicated that the proteasome is involved in the degradation of many membranebound and soluble proteins within the secretory pathway
(Brodsky and McCracken, 1997). This includes wild-type
connexin43 (Cx43), whose turnover rate has been reported
to be reduced by proteasomal inhibitors (Laing and Beyer,
1995). The role of the proteasome in the turnover of wildtype (WT) Cx32 is not known, nor has the mechanism of
degradation of mutant connexins been addressed.
In the current study, we present the first integrated analysis of the intracellular transport, assembly, and degradation of CMTX-linked Cx32 mutants. We use a combination
of biochemical and morphological techniques to examine the
post-translational fate of the R142W, E186K, and E208K
CMTX-linked Cx32 mutants expressed in stable transfectants of PC12 cells. Our results provide new insights into the
pathophysiology of CMTX disease as well as into the quality
control mechanisms that govern the fidelity of assembly of
connexins into gap junctional plaques.

MATERIALS AND METHODS
Cell Culture
The generation of multiple independent clonal lines of PC12J cells (a
subclone of rat pheochromocytoma cells devoid of endogenous gap
junction activity) stably expressing either wild-type human Cx32 or
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a CMTX-linked Cx32 mutant has been described by Deschenes et al.
(1997). In brief, the coding regions of wild-type or mutant (E208K,
R142W, or E186K) Cx32 were amplified from the genomic DNA of
control subjects or CMTX patients, respectively, and subcloned into
the pREP9 expression vector for transfection; vector-only transfectants served as controls. Cell lines were maintained in RPMI 1640
medium supplemented with 10% horse serum, 5% FCS, penicillin G,
streptomycin, and 400 g/ml G418 (Deschenes et al., 1997). Expression of endogenous Cx32 in the rat hepatoma cell line MH1C1 (a
generous gift from R. Ruch, Medical College of Ohio, Toledo, OH)
was enhanced by culturing for 48 h in the presence of 10 M
dexamethasone as previously described (Ren et al., 1994). Mouse
sarcoma cells stably transfected with the adhesion molecule liver
cell adhesion molecule (L-CAM) (S180L) (Mege et al., 1988) were
maintained in Dulbecco’s modified Eagle’s medium plus 10% FCS,
penicillin G, and streptomycin, and Chinese hamster ovary (CHO)K1 cells were maintained in F-12 medium containing 10% FCS.

Antibodies and Reagents
Mouse monoclonal antibody 7C6.C7 specific for Cx32 was a generous gift of E. Hertzberg (Albert Einstein College of Medicine, Bronx,
NY) and used for all immunofluorescence microscopy. For immunoprecipitation of Cx32, crude antiserum from rabbits immunized
with a synthetic peptide corresponding to amino acids 98 –124 of rat
Cx32 (kindly provided by D. Goodenough, Harvard Medical
School, Boston, MA; Goodenough et al., 1988) was used in pulse–
chase experiments, whereas affinity-purified polyclonal rabbit antiCx32 immunoglobulin G (IgG) purchased from Zymed (San Francisco, CA; 71-0600) was used for cross-linking analysis. Cx43 was
immunoprecipitated with affinity-purified polyclonal rabbit antiCx43 antibodies prepared as previously described (Musil et al.,
1990), and L-CAM was immunoprecipitated with a polyclonal rabbit antiserum kindly provided by W. Gallin (University of Alberta,
Edmonton, Alberta, Canada). Marker proteins for the ER (calreticulin) and Golgi stack (mannosidase II) were immunodetected using
monospecific polyclonal rabbit antisera from Affinity BioReagents
(Golden, CO; PA3-900) and K. Moreman (University of Georgia,
Athens, GA), respectively. FITC-conjugated donkey anti-mouse IgG
(Jackson ImmunoResearch, West Grove, PA) and rhodamine-conjugated goat anti-rabbit IgG (Pierce, Rockford, IL) were
used as secondary antibodies.
Unless otherwise noted, all reagents were from Sigma (St. Louis,
MO). Stock solutions of proteasomal inhibitors were prepared in
DMSO at the following concentrations and stored at ⫺20°C: 26 mM
N-acetyl-leu-leu-norleucinal (ALLN), 1 mM lactacystin, and 5 mM
carboxybenzyl-leucyl-leucyl-leucyl-vinylsulphone (ZL3VS). ZL3VS
was a kind gift from M. Bogyo (Harvard Medical School). A concentrated stock of chloroquine (10 mM) was freshly prepared in
double-distilled H2O (ddH2O) for each experiment. Other reagents
were stored as concentrated stocks at 20°C: leupeptin (10 mg/ml in
ddH2O), cycloheximide (2 mg/ml in ddH2O), and brefeldin A (BFA;
Epicentre, Madison WI; 5 mg/ml in ethanol). Final concentrations in
experiments were as follows: 100 M ALLN, 10 M lactacystin, 20
M ZL3VS, 100 g/ml leupeptin, 20 g/ml cycloheximide, 200 M
chloroquine, and 6 g/ml BFA.

Immunofluorescence Microscopy
Glass coverslips in 96-well dishes were treated with a solution of 0.5
mg/ml poly-d-lysine (Sigma; P7886) in 0.15 M boric acid, pH 8.4 for
ⱖ30 min at 37°C and rinsed twice with PBS without Ca2⫹ and Mg2⫹.
PC12 transfectants were plated onto the coated coverslips and used
for experiments after 4 d of culture, when ⬃75% confluent. For
experiments at 37°C, the plating medium was replaced with fresh
culture medium (with or without additions). Incubations at 20°C
were conducted in Leibovitz’s L15 medium (Life Technologies,
Gaithersburg, MD; 11415-023) supplemented with 10% horse serum,
5% FCS, penicillin G, and streptomycin, in an ambient air (no CO2)

refrigerator maintained at 20°C with a heating unit in a cold room
as described in VanSlyke and Musil (2000).
At the time points specified in the figure legends, cells were
rinsed three times with cold PBS (with Ca2⫹ and Mg2⫹) before fixing
with prechilled 2% paraformaldehyde in PBS for 30 min at room
temperature. After fixation, cells were washed and then incubated
in PBS for at least 30 min. Coverslips were incubated 30 – 60 min in
blocking buffer (PBS plus 0.5% normal goat serum, 0.1% BSA, 0.2%
Triton X-100, and 0.02% sodium azide) before addition of the desired primary antibody (or, in the case of double labeling, antibodies) diluted in blocking buffer. Hybridoma supernatant containing
7C6.C7 anti-Cx32 antibodies was used diluted 1:1. After an overnight incubation at 4°C in a humidified chamber, cells were incubated for 30 min in blocking buffer and then incubated with the
appropriate secondary antibody for 1.5 h at room temperature
followed by another 30-min rinse in blocking buffer. The coverslips
were mounted onto glass slides with MOWIOL 4 – 88 mounting
medium (Calbiochem, La Jolla, CA), and immunofluorescence images were captured using a Leica (Nussloch, Germany) DM LD
photomicrography system and Scion (Frederick, MD) Image 1.60
software.

Metabolic Labeling
For metabolic labeling at 37°C, cells were first starved for methionine for 30 min at 37°C in Dulbecco’s modified Eagle’s medium
lacking methionine supplemented with 5% dialyzed FCS and 2 mM
glutamine (“labeling” medium). The medium was then replaced
with fresh labeling medium containing [35S]methionine
(EXPRE35S35S; New England Nuclear, Boston, MA; 0.3 mCi/60-mm
dish of cells, scaled proportionally for dishes of other sizes). For
pulse– chase analysis, the radioactive medium was removed after a
30-min pulse and the cultures were rinsed once before addition of
fresh complete culture medium supplemented with 0.5 mM nonlabeled methionine. For metabolic labeling at 20°C for analysis of
Triton X-100 solubility (see Figure 3), cells in 60-mm dishes were
incubated in 2.5 ml of reduced bicarbonate labeling medium (Earle’s
minimal essential medium lacking methionine and containing 15
mM HEPES, 0.35 g/l bicarbonate, 2 mM glutamine, and 5% dialyzed FCS) containing 0.3 mCi of [35S]methionine at 37°C under
ambient CO2 conditions. For analysis of connexon assembly at 20°C
(see Figure 8), cells in 60-mm dishes were first incubated in 2.5 ml of
reduced bicarbonate labeling medium for 30 min at 37°C under
ambient CO2 conditions. The medium was replaced with 2.5 ml of
fresh reduced bicarbonate labeling medium containing 0.3 mCi of
[35S]methionine, and the cells were incubated at 37°C for 20 min
under the same conditions before chilling the tissue culture dish
briefly to 4°C and continuing the labeling for an additional 4 h 40
min in a 20°C ambient CO2 incubator (VanSlyke and Musil, 2000).
The initial 20 min of labeling at 37°C increases the amount of
radiolabeled connexin synthesized but is too short to permit detectable assembly of wild-type Cx32 into Triton X-100-insoluble gap
junctional plaques.

Immunoprecipitation
With the exception of cells to be lysed under nondenaturing conditions in Triton X-100 (see below), cells were rinsed once with PBS at
4°C and resuspended in lysis buffer (5 mM Tris base, 5 mM EDTA,
5 mM EGTA, 10 mM iodoacetamide, and 2 mM PMSF, pH 8.0)
supplemented with 0.6% SDS, 250 g/ml soybean trypsin inhibitor,
and 200 M leupeptin. The lysates were then immunoprecipitated
with the desired antibody as described by Le and Musil (1998). Two
modifications were made for immunoprecipitation of Cx32: first,
cells were lysed in SDS at room temperature for 30 min instead of at
100°C for 3 min to minimize aggregation of Cx32; and second,
samples were precleared with protein A-Sepharose for 2 h at 4°C
before addition of anti-Cx32 antibody (VanSlyke and Musil, 2000).
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Triton X-100 Solubilization and Chemical CrossLinking
Metabolically labeled tissue culture cells were resuspended in incubation buffer (136.8 mM NaCl, 5.36 mM KCl, 0.336 mM Na2HPO4,
0.345 mM KH2PO4, 0.8 mM MgSO4, 2.7 mM CaCl2, and 20 mM
HEPES, pH 7.5) and solubilized in the presence of 1% Triton X-100
on ice for 30 min as previously described (Musil and Goodenough,
1993). The cell extract was separated into Triton X-100-insoluble and
-soluble fractions by centrifugation at 100,000 ⫻ g (45,000 rpm in a
TLA100.3 tabletop ultracentrifuge; Beckman Instruments, Palo Alto,
CA) for 50 min at 4°C. For analysis of Cx32 Triton X-100 solubility
(see Figure 3), each fraction was lysed in SDS and immunoprecipitated as described for Cx43 (Musil and Goodenough, 1991), except
that the samples were lysed in SDS at room temperature for 30 min
and precleared with protein A-Sepharose as described above. For
cross-linking analysis of Cx32 connexons, the Triton X-100-soluble
fraction was incubated for 30 min on ice with 1 mM ethylene
glycolbis(succinimdylsuccinate) (EGS; Pierce), freshly diluted from
a 100 mM stock in DMSO. The cross-linking reaction was stopped
by addition of glycine as detailed by Musil and Goodenough (1993),
SDS was added to a final concentration of 0.6%, and the sample was
incubated for 30 min at room temperature before immunoprecipitation of Cx32 as described above. Mock cross-linked control samples were treated identically but received DMSO only.

SDS-PAGE and Quantification
Monomeric Cx32, Cx43, and L-CAM immunoprecipitates were analyzed on 11, 10, or 7.5% SDS-PAGE gels, respectively, after incubation of samples in SDS-PAGE sample loading buffer for either 30
min at room temperature (Cx32) or for 3 min at 100°C (Cx43 and
L-CAM). Samples containing cross-linked Cx32 were warmed to
37°C for 5 min before analysis on 7.5–12.5% gradient gels. The dried
gels were quantitated on a 445 SI PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using IPLab Gel software (Signal Analytics,
Vienna, VA).

RESULTS
Intracellular Localization of the R142W, E186K, and
E208K CMTX-linked Cx32 Mutants in PC12 Cell
Transfectants
We examined three CMTX-linked Cx32 point mutants reported by Deschenes et al. (1997) to be associated with moderate to severe clinical disease. The R142W mutation converts arginine 142 to a tryptophan in a position within the
third transmembrane domain of Cx32 that is occupied by a
basic residue in all known members of the connexin family
and that is thought to contribute to the gap junction channel
pore. The E186K mutation changes the charge of an amino
acid at the end of the second extracellular loop that is
perfectly conserved within the connexin family, whereas the
E208K mutation similarly reverses the polarity of another
perfectly conserved glutamic acid residue that borders the
last transmembrane domain. These mutants have been reported to be nonfunctional when expressed in paired Xenopus oocytes (Bruzzone et al., 1994; Castro et al., 1999).
Figure 1 shows the steady-state localization of these mutants and WT Cx32 when stably expressed in otherwise
connexin-deficient PC12 transfectants. WT Cx32 accumulated on the cell surface and concentrated at cell– cell interfaces in the punctate distribution characteristic of gap junctional plaques (Figure 1A; also see Figure 5A). As previously
reported (Deschenes et al., 1997), the R142W, E186K, and
E208K Cx32 mutants instead were localized by immunoflu1936

Figure 1. Steady-state intracellular localization of WT Cx32 and
CMTX-linked Cx32 mutants. PC12 cell lines expressing WT Cx32
(A), R142W Cx32 (C and D), E186K Cx32 (E and F), or E208K Cx32
(G and H) or transfected with vector only (B) were fixed and
immunostained with anti-Cx32 antibodies (A, C, E, and G). Cells
expressing CMTX-linked Cx32 mutants were doubly immunostained for markers specific for either the cis/medial-Golgi (mannosidase II; D and F) or the ER (calreticulin; H). Arrows (C–F) point to
Golgi regions doubly stained for Cx32 and mannosidase II.

orescence microscopy exclusively intracellularly in multiple
independent clones (Figure 1; also see Figure 5). They were
also undetectable on the plasma membrane by cell surface
biotinylation (our unpublished data). Accumulation of immunodetectable E208K, R142W, or E186K Cx32 on the cell
surface could not be induced by incubating the cells for 48 h
at either 25 or 27°C (our unpublished data). The trafficking
defect of these mutants is therefore distinct from that of the
⌬F508 form of the cystic fibrosis transmembrane conductance regulator (CFTR), which is retained within the ER at
37°C but is transported to the cell surface at lower temperatures (Denning et al., 1992).
Double-staining immunofluorescence microscopy studies
revealed differences in the subcellular localization of the
CMTX-linked Cx32 mutants. E208K Cx32 showed nearly
perfect colocalization with an ER marker (calreticulin) in a
distribution readily distinguishable from that obtained with
a Golgi resident (mannosidase II) (Figure 1). In each of the
E208K Cx32-expressing PC12 clonal cell lines we have examined, the perinuclear, Golgi-like staining pattern described by Deschenes et al. (1997) in a minority of highly
expressing cells was not observed. Possibly, such transfecMolecular Biology of the Cell
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tants were selected out of the population during repeated
passage. The intracellular localization of E208K Cx32 was
unaffected by treatments that accumulate newly synthesized, transport-competent secretory proteins within either
the peripheral elements of the intermediate compartment or
the Golgi apparatus (16°C, nocodazole; 20°C, monensin)
(Matlin and Simons, 1983; Hsu et al., 1991; Jackson et al.,
1993; our unpublished results). The E186K and R142W Cx32
mutants could also be detected within the ER. In contrast to
E208K Cx32, however, their staining pattern was not restricted to this organelle but instead included Golgi-like
perinuclear compartments where they colocalized with
mannosidase II. These findings suggest that E208K Cx32
remains confined to the ER, whereas the R142W and E186K
mutants are competent to traffic to more distal compartments of the secretory pathway but not to the cell surface.

Rapid Turnover of WT and Mutant Cx32 in
PC12 Cells
As defined by Aridor and Balch (1999), class II mutations
are distinguished from class I defects in that they inhibit
not only the intracellular transport but also the degradation of the affected protein, leading to deleterious overaccumulation within the early secretory pathway. Reduced
turnover of disease-causing mutants of both soluble and
integral plasma membrane proteins has been recapitulated in tissue culture cell systems (Graham et al., 1990;
Sadeghi et al., 1997; Skovronsky et al., 1998). In some (but
not all) cases, both the trafficking and degradation defects
of class II mutants are associated with polymerization of
the affected protein in aggregates insoluble in the nonionic detergent Triton X-100 (Graham et al., 1990; Kim and
Arvan, 1998; Skovronsky et al., 1998). To investigate
whether the E208K, R142W, and E186K Cx32 mutants
behave like class I or class II mutants in PC12 transfectants, we examined their rate of turnover (Figure 2) and
detergent sensitivity (Figure 3). Less than 30% of WT Cx32
metabolically labeled with [35S]methionine during a 30min pulse was immunoprecipitable after a 4-h chase, as
expected from the rapid rate of degradation typical of
Cx32 and other members of the connexin family in cultured cells as well as in vivo (Fallon and Goodenough,
1981; Musil et al., 1990; Beardslee et al., 1998). As assessed
by pulse– chase analysis, each of the three CMTX-linked
Cx32 mutants tested was degraded at least as rapidly as
the wild-type protein (Figure 2), whereas a [35S]methionine-labeled, metabolically stable cellular protein (actin)
was not detectably turned over during the same period
(our unpublished data). To assess the detergent solubility
of WT and mutant forms of Cx32, PC12 transfectants
labeled for 4 h with [35S]methionine were lysed in 1.0%
Triton X-100 at 4°C (Figure 3). Previous studies have
demonstrated that newly synthesized WT Cx43 is soluble
under these conditions and acquires resistance to Triton
X-100 only upon incorporation into gap junctional
plaques (Musil and Goodenough, 1991). We show here
that WT Cx32 has similar properties. [35S]methioninelabeled Cx32 endogenously expressed in MH1C1 hepatoma cells was essentially completely (⬎96%) Triton soluble when metabolically labeled at 20°C, a temperature at
which transport to the plasma membrane and therefore
formation of gap junctional plaques are inhibited (Matlin

Figure 2. Pulse– chase analysis of the turnover of WT Cx32 and
CMTX-linked mutants. PC12 transfectants were metabolically labeled with [35S]methionine for 30 min at 37°C and then chased in the
presence of excess cold methionine for 0, 2, or 4 h. Cx32 was
immunoprecipitated from equal volumes of total cell lysate (and
therefore from equal numbers of cell equivalents) and analyzed by
SDS-PAGE. The amount of [35S]methionine-Cx32 recovered by immunoprecipitation after each chase period was expressed as a percentage of [35S]methionine-Cx32 immunoprecipitable immediately
after the pulse.

and Simons, 1983). In contrast, a considerable amount
(45%) of [35S]methionine-labeled Cx32 synthesized at
37°C was insensitive to Triton X-100. Given the wellknown insolubility of Cx32 gap junctional plaques in most
nonionic detergents (Hertzberg, 1984), the acquisition of
Triton X-100 resistance of Cx32 in MH1C1 cells at 37°C is
likely to be due to gap junction assembly. WT Cx32 expressed in PC12 cells showed a comparable temperature
dependence in its response to Triton X-100, in keeping
with their ability to form gap junctional plaques. In contrast, each of the three CMTX-linked Cx32 mutants examined could be almost completely (⬎95%) solubilized by
Triton X-100 when synthesized at 37°C. Examination of
the total cellular pool of mutant Cx32 by Western blotting
also failed to provide evidence of accumulation in stable
high-molecular-weight aggregates (our unpublished results). The R142W, E186K, and E208K forms of Cx32 therefore behave differently than the PiZ mutant of ␣1-antitrypsin, of which a fraction too small to be detectable by
short-term metabolic labeling slowly accumulates in degradation-resistant, Triton X-100-insoluble aggregates that
over time become the predominant cellular form of the
protein as assessed by immunoblotting (Graham et al.,
1990).
1937
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Figure 3. Solubility of WT Cx32 and CMTX-linked mutants in
Triton X-100. Cx32-expressing cells were metabolically labeled with
[35S]methionine for either 4 h at 37°C or 5 h at 20°C. Cells were lysed
in 1% Triton X-100 at 4°C and subjected to centrifugation at
100,000 ⫻ g for 50 min. Cx32 was immunoprecipitated from the total
extract (T), Triton X-100-soluble supernatant (S), and Triton X-100insoluble pellet (P) and analyzed by SDS-PAGE. In all cases, recovery of radiolabeled Cx32 (S ⫹ P/T) was ⱖ93%. N.D., not determined.

Pathways of WT Cx32 Degradation
The rapidity with which both WT and mutant forms of Cx32
are turned over despite their disparate subcellular localizations raised the question of whether they were degraded by
the same or distinct mechanisms. To examine this issue, we
treated PC12 cell transfectants with inhibitors of either the
lysosome or the proteasome, the two major pathways implicated in the destruction of integral plasma membrane proteins (Seglen, 1983; Lee and Goldberg, 1998).
We first investigated the mechanism(s) by which WT Cx32
is degraded by pulse– chase analysis (Figure 4). To inhibit
lysosomal degradation, we used the tripeptide leupeptin
instead of a weak base to avoid the potentially confounding
effect of the latter on Golgi intracisternal pH and function
(Seglen, 1983; Stevens and Forgac, 1997). Addition of leupeptin to the chase medium modestly but reproducibly increased the amount of pulse-labeled Cx32 that survived a
6-h chase by ⬃1.5-fold. A much greater inhibition of degradation was achieved in the presence of the proteasome
inhibitor ALLN (Figure 4). In a more limited series of experiments, a mechanistically distinct, highly selective blocker of
the proteasome (ZL3VS) had a comparable effect, increasing
the amount of pulse-labeled [35S]methionine-WT Cx32 that
survived a 6-h chase an average of 2.3-fold (⫾0.35; n⫽3). The
relative efficacy of proteasomal and lysosomal inhibitors in
slowing WT Cx32 turnover is very similar to that previously
reported by Laing and Beyer (1995) for WT Cx43 endogenously expressed in a CHO cell subclone.
The role of lysosomes in the turnover of at least a fraction
of WT Cx32 molecules was corroborated by immunofluores1938

Figure 4. Pulse– chase analysis of degradation of WT Cx32 and
CMTX-linked Cx32 mutants. PC12 cell transfectants were metabolically labeled for 30 min with [35S]methionine and then chased at
37°C for 6 h in either the absence or presence of 100 M ALLN or
100 g/ml leupeptin. Cx32 was immunoprecipitated from equal
volumes of total cell lysate (and therefore from equal numbers of
cell equivalents) and analyzed by SDS-PAGE. The data are presented as the fold increase in the percent recovery of Cx32 after a 6-h
chase in the presence of inhibitors relative to the percent recovery of
Cx32 in the absence of inhibitors.

cence microscopy (Figure 5). Unlike leupeptin, weak bases
such as chloroquine inactivate proteases within endosomes
and lysosomes by neutralizing lumenal pH. A consequence
of this activity is osmotic swelling of these compartments
into characteristic “doughnut” structures that are morphologically distinct from the Golgi and other normally acidic
organelles (Mellman et al., 1986). WT Cx32 could be readily
detected in such distended vesicles after a 3- to 6-h incubation of cells with 200 M chloroquine (Figure 5C). In contrast, proteasome inhibitors including ALLN (Figure 5B) and
ZL3VS (our unpublished results) did not detectably change
the pattern of WT Cx32 staining.
Proteasome inhibitor-sensitive degradation of integral
plasma membrane proteins has been reported to occur before their exit from the ER and/or after their transport to the
cell surface (reviewed by Bonifacino and Weissman, 1998).
Although evidence that WT Cx43 may be subjected to proteasomal degradation at the latter site has been reported by
Laing et al. (1997), it is unknown whether this process is also
involved in connexin turnover at earlier stages of the secretory pathway. Connexins are not glycosylated or known to
undergo any other type of post-translational modification
that could be used to biochemically monitor their transport
through the cell. The extent of proteasome inhibitor-sensitive turnover of WT Cx32 in the ER was therefore assessed
by conducting pulse– chase experiments in the presence of
BFA, which blocks the vesicular export of newly synthesized
proteins from this compartment (Klausner et al., 1992) (FigMolecular Biology of the Cell
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Figure 5. Effect of lysosomal and proteasomal inhibitors on WT and mutant Cx32 immunostaining. PC12 cell transfectants expressing WT Cx32
(A–C), R142W Cx32 (D–G), E186K Cx32 (H–K), or E208K Cx32 (L–N) were stained for Cx32 after incubation for 6 h at 37°C with medium alone
(A, D, H, and L), 100 M ALLN (B, E, I, and M), 200 M chloroquine (C, F, J, and N), or 100 g/ml leupeptin (G and K). Insets in G and K, cells
were chased with 20 g/ml cycloheximide in the presence of 100 g/ml leupeptin for 3.5 h at 37°C.

ure 6). To examine only the initial stages of connexin degradation, and because connexins might become subject to
additional, physiologically irrelevant proteolytic pathways
during prolonged exposure to BFA, we labeled cells for only
30 min and limited our analysis to a 2- to 3-h chase. During
this period, BFA did not slow the degradation of WT Cx32 in
PC12 cell transfectants. Turnover of WT Cx32 in either the
absence or presence of BFA was efficiently inhibited by
the proteasome inhibitor ALLN. BFA also had very little
effect on the degradation of endogenously expressed WT
Cx32 in MH1C1 cells or WT Cx43 in CHO, normal rat
kidney, L929, or primary lens epithelial cells (CHO data
shown in Figure 6). In all cell types examined, general
ER–Golgi trafficking was sensitive to BFA as verified by
redistribution of mannosidase II into the ER (our unpublished results). Rapid, proteasome-mediated degradation
in the ER is therefore not limited to a single connexin
species or an artifact of exogenous connexin expression.
Control experiments demonstrated that BFA strongly inhibited the otherwise rapid (t1/2 ⬃3 h) degradation of the
connexin-unrelated integral plasma membrane protein LCAM (Figure 6), demonstrating that ER degradation is not
a general consequence of BFA treatment but instead reflects a specific property of connexins.

Pathways of Mutant Cx32 Degradation
Having examined the role of the lysosome and proteasome in
WT Cx32 turnover, we next investigated the involvement of
these pathways in the degradation of the E208K, R142W, and
E186K CMTX-linked Cx32 forms. Pulse– chase analysis revealed that all three mutants were as sensitive to the proteasome inhibitor ALLN as the wild-type protein (Figure 4). The
lysosomal inhibitor leupeptin enhanced the recovery of the
R142W mutant to about the same extent as it did WT Cx32 but
did not influence the turnover of E208K Cx32, in keeping with
the exclusively ER immunolocalization pattern of the latter
mutant at steady state (Figure 1). Surprisingly, leupeptin also
had no detectable effect on the turnover of the E186K Cx32
mutant despite its ability to traffic to post-ER compartments.
Participation of the lysosome in the degradation of R142W
Cx32, but not of the E186K or E208K mutants, was supported by immunolocalization studies (Figure 5). Similar to
its effect on WT Cx32, chloroquine treatment of R142W
Cx32-expressing cells caused some of the mutant molecules
to accumulate in swollen vesicles with the characteristic
doughnut-like morphology taken on by components of the
endosome–lysosome system in the presence of this lysosomotropic amine (Figure 5F). In contrast, neither the E186K
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Figure 6. Degradation of wild-type connexins retained within the
ER. WT Cx32-expressing PC12 cell transfectants, CHO cells endogenously expressing WT Cx43, and L-CAM-expressing S180L cells
were pulse-labeled for 30 min with [35S]methionine in the absence
or presence of 6 g/ml BFA. Cells were then chased (with or
without BFA) for 2, 3, or 6 h, respectively. BFA causes retention of
newly synthesized proteins within the ER. Where indicated, 100 M
ALLN was included in the chase medium. The data are presented as
the fold increase in the percent recovery of pulse-labeled protein
(Cx32, Cx43, or L-CAM) after the chase period in the presence of
inhibitor(s) relative to the percent recovery of pulse-labeled protein
in the absence of inhibitor. Recovery after chase in the absence of
inhibitors (control) averaged 56% for WT Cx32 and 60% for WT
Cx43. Complete inhibition of Cx degradation (⫽100% recovery)
therefore corresponds to a 1.8-fold increase in recovery of WT Cx32
and a 1.7-fold increase in recovery of WT Cx43, very close to the
values obtained in the presence of ALLN either with or without
BFA. For each experimental condition, n ⫽ 3.

(Figure 5J) nor the E208K (Figure 5N) Cx32 mutant was
detected in such distended vesicles after chloroquine exposure. R142W Cx32 (Figure 5G), but not the E186K species
(Figure 5K), could also be observed in lysosome-like punctate structures after treatment of cells with leupeptin. Because leupeptin does not cause vacuolar swelling, staining
of R142W Cx32 in the endosome–lysosome system was often
not obvious above anti-Cx32 immunoreactivity in the ER but
became readily detectable if cycloheximide was used to
chase preexisting Cx32 into post-ER compartments (Figure
5G, inset). The proteasome inhibitor ALLN increased the
intensity but did not change the pattern of staining of the
R142W, E186K, or E208K Cx32 species (Figure 5, E, I, and
M). The transport defects of these mutants therefore cannot
be overcome by reducing their proteasomal turnover.
Although successfully used to assess the role of the proteasome in the turnover of a wide variety of proteins, ALLN
also inhibits certain lysosomal cathepsins as well as calpains
(Lee and Goldberg, 1998). To rule out the possibility that the
effect of ALLN on the degradation of the Cx32 mutants was
1940

Figure 7. Effect of lysosomal and proteasomal inhibitors on E208K
Cx32 degradation. E208K Cx32-expressing cells were incubated for 6 h
at 37°C in either the absence (A) or presence (B–I) of 20 g/ml cycloheximide with the following additions: 100 M ALLN (C), 20 M
Cbz-leu-leu-leucinal (D), 10 M lactacystin (E), 20 M ZL3VS (F), 100
g/ml leupeptin (G), 200 M chloroquine (H), or 100 M ALLM (I).

due to nonproteasomal activity of the drug, we conducted
immunocytochemical studies using the protein synthesis
blocker cycloheximide. Control experiments demonstrated
that 20 g/ml cycloheximide effectively inhibited incorporation of [35S]methionine into nascent proteins within 10 min
and did not alter the rate of degradation of previously
synthesized [35S]methionine-labeled E208K Cx32, R142W
Cx32, or E186K Cx32 (our unpublished results). Incubation
of cells expressing these mutants with cycloheximide for 6 h
resulted in the almost complete loss of anti-Cx32 immunoreactivity, in keeping with their rapid rate of degradation.
As expected from pulse– chase analysis (Figure 4), the disappearance of mutant staining in cycloheximide-treated
cells was largely prevented by ALLN (data for E208K Cx32
shown in Figure 7 and for E186K Cx32 in Figure 8). Similar
results were obtained with the related proteasome inhibitor
Cbz-leu-leu-leucinal as well as with two highly selective,
mechanistically distinct blockers of proteasomal proteolysis,
ZL3VS and lactacystin (data for E208K Cx32 shown in Figure
7). The specificity of this effect for proteasomal inhibitors
was demonstrated using the E208K Cx32 mutant, which in
pulse– chase experiments was shown to be insensitive to
leupeptin (Figure 4). Neither leupeptin (Figure 7G) nor the
mechanistically unrelated lysosomal inhibitor chloroquine
(Figure 7H) was able to prevent the loss of immunologically
Molecular Biology of the Cell
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Cx32 and Cx43 (L.S. Musil, unpublished results), the aforementioned ability of ZL3VS to reduce WT Cx32 turnover in
pulse– chase experiments strongly supports a role for the
proteasome in the turnover of this species as well.

E186K Cx32 Undergoes Retrograde Transport Back
to the ER

Figure 8. Retrograde transport of E186K Cx32. E186K Cx32-expressing PC12 cell transfectants were incubated at 20°C for 3 h and
then either fixed immediately (A and B) or shifted to 37°C in the
presence of 20 g/ml cycloheximide. The latter cells were incubated
at 37°C for either 1 h (C–F) or 6 h (G and H) in the absence of further
additions or for 6 h in the presence of 100 M ALLN (I and J). All
cells were immunostained for Cx32 and in some cases doubly
stained for the cis/medial-Golgi (mannosidase II; B, D, H, and J) or
the ER (calreticulin; F). Arrows in C and D point to regions that stain
for Cx32 but not mannosidase II; arrows in E and F indicate areas of
colocalization of Cx32 and calreticulin.

detectable E208K Cx32 in cycloheximide-treated cells. Furthermore, ALLM, closely related to ALLN and an effective
blocker of calpains and cathepsins but not of the proteasome
(Rock et al., 1994), had a much weaker effect on E208K Cx32
recovery than did ALLN, lactacystin, or ZL3VS (Figure 7I).
Although comparable experiments were not possible with
WT Cx32 because of the fact that cycloheximide itself
strongly inhibits degradation of wild-type forms of both

Proteasome-mediated degradation in the early secretory
pathway requires that the substrate protein, in either an
intact or partially degraded state, be extracted from membranes and inserted into cytosolic proteasomes (reviewed by
Plemper and Wolf, 1999). To date, the ER is the only intracellular site at which this “dislocation” process has been
reported to occur. Given that E186K Cx32 does not enter the
endosome–lysosome system or traffic to the cell surface, the
question arises of how this mutant is degraded from post-ER
compartments. To address this issue, we took advantage of
the serendipitous observation that a 3-h incubation of living
cells at 20°C caused E186K Cx32 to concentrate very strongly
within the Golgi region (Figure 8A). To study the fate of this
post-ER pool of E186K Cx32, we returned cells to 37°C in the
presence of cycloheximide to inhibit new protein synthesis.
Beginning at ⬃10 min after warm-up, the perinuclear staining pattern of the mutant was gradually replaced by a more
diffuse, reticular distribution that was most striking 30 –50
min later (Figure 8, C and E). Double-staining immunofluorescence microscopy demonstrated that the mutant now
colocalized predominantly with the ER marker calreticulin
(Figure 8F) instead of with mannosidase II (Figure 8D),
indicating that it had undergone retrograde transport back
into the ER. This interpretation is in keeping with previous
data suggesting that Golgi-to-ER transport is inhibited to a
greater extent at 20°C than anterograde ER-to-Golgi movement, leading to a relative accumulation of transport-competent proteins in the Golgi at 20°C that is reversed upon
return to 37°C (Hsu et al., 1991; Cole et al., 1996). Immunodetectable E186K Cx32 disappeared over the next 5 h (Figure
8G), as expected from its rapid rate of turnover in either the
absence (Figure 2) or presence (our unpublished results) of
cycloheximide as determined by pulse– chase analysis. Degradation of E186K Cx32 over the same period, but not its
retrograde transport to the ER, was blocked by the proteasome inhibitor ALLN (Figure 8I). Taken together with the
data in Figures 4 and 5, these results indicate that E186K
Cx32 is turned over by a proteasome-mediated pathway
even after its initial exit from the ER. Degradation of such
post-ER pools of E186K Cx32 may require retrieval back into
the endoplasmic reticulum, from which it might access the
proteasome via the translocon channel.

Effect of CMTX-linked Cx32 Mutations on
Connexon Assembly
The first step in gap junction formation is the noncovalent
assembly of six connexin monomers into a connexon before
transport to the cell surface. It has been suggested that the
ability of intracellularly retained CMTX-linked Cx32 mutants to act as dominant negative inhibitors of WT connexins
is due to the formation of mixed connexons (Omori et al.,
1996; Deschenes et al., 1997). To assess the competence of the
R142W, E186K, and E208K Cx32 mutants to undergo connexon assembly, we assayed their oligomerization state
1941
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Figure 9. CMTX-linked Cx32
mutants do not assemble connexons. PC12 cells expressing WT
Cx32 (lanes 3 and 4), mutant Cx32
(lanes 5–10), or no Cx32 (lanes 11
and 12) were metabolically labeled for 20 min at 37°C and then
4.6 h at 20°C as described in MATERIALS AND METHODS. Alternatively, MH1C1 cells (lanes 1 and
2) were labeled for 4 h at 37°C.
Triton X-100-solubilized cell extracts were cross-linked with 1
mM EGS for 30 min at 4°C (lanes
2, 4, 6, 8, 10, and 12), or treated
with DMSO only for a mock–
cross-linked control (lanes 1, 3, 5,
7, 9, and 11). Cx32 was immunoprecipitated and analyzed by
SDS-PAGE on 7.5–12.5% gradient
gels. The positions of monomeric Cx32 (m) and cross-linked Cx32 connexons (cxon) are indicated at the left. The bands migrating slower
than monomeric Cx32 in non– cross-linked mutant immunoprecipitates are mainly SDS-induced aggregates of Cx32.

when expressed individually in PC12 cell transfectants (Figure 9). We first verified that assembly of WT Cx32 into
connexons could be detected using techniques previously
established for Cx43 (Musil and Goodenough, 1993). Cells
were metabolically labeled with [35S]methionine and then
lysed in the presence of Triton X-100 at 4°C before crosslinking of the soluble fraction with EGS and analysis of Cx32
oligomers by immunoprecipitation and SDS-PAGE. As expected, WT Cx32 in PC12 transfectants could be cross-linked
to an ⬃150-kDa species indistinguishable from Cx32-containing connexons isolated from MH1C1 cells (Figure 9, lanes
2 and 4) or rat liver (our unpublished results; Cascio et al.,
1995). In contrast, none of the three mutants could be crosslinked into a detectable connexon species (Figure 9, lanes 6,
8, and 10) despite expression levels roughly equivalent to
(E186K and R142W) or somewhat greater than (E208K) that
of WT Cx32. Similar results were obtained if cells were
labeled at 37°C in the presence of ALLN to reduce the rate of
connexin degradation (our unpublished results), indicating
that rapid turnover is not responsible for the inability of the
mutants to assemble into connexons.

DISCUSSION
Although defects in the Cx32 gene were identified as the
cause of CMTX disease more than 7 years ago (Bergoffen et
al., 1993), the mechanism(s) by which these mutations lead
to peripheral nerve pathology have not been deliniated. In
this study we have examined the assembly, trafficking, and
degradation of three CMTX-linked Cx32 point mutants stably expressed in PC12 cell transfectants. The E208K, R142W,
and E186K Cx32 mutants were undetectable on the cell
surface by either morphological (immunofluorescence microscopy) or biochemical (cell surface biotinylation) assays.
Insofar as oligomeric assembly is a general prerequisite for
the trafficking of multisubunit proteins to the cell surface
(Hammond and Helenius, 1995), the inability of these mutants to form connexons is also consistent with their intracellular retention. Two major conclusions arise from our
findings and are discussed below. First, the E208K, R142W,
1942

and E186K Cx32 mutations are unlikely to cause CMTX by
accumulating in poorly degradable intracellular aggregates.
Second, each of these mutants has a distinct intracellular
trafficking and degradative fate, revealing a multistep quality control mechanism that prevents abnormal connexins
from being transported to the plasma membrane.

Implications for the Mechanism of CMTX Disease
By definition, mutations that prevent the transport of a
plasma membrane protein to the cell surface cause the loss
of the protein’s wild-type function. As described by Aridor
and Balch (1999), class I mutations result in the efficient
degradation of the affected secretory protein at the level of
the ER by a proteasome-mediated process. Class II mutations inhibit the protein’s turnover as well as its intracellular
transport, resulting in chronic, pathological activation of ER
stress responses and in some cases misfolding of the accumulated mutant protein into Triton X-100-insoluble aggregates (Kim and Arvan, 1998; Aridor and Balch, 1999). Three
lines of evidence indicate that the E208K, R142W, and E186K
CMTX-linked forms of Cx32 behave as class I instead of class
II mutants in PC12 cell transfectants. First, pulse– chase analysis revealed that all three mutants, like wild-type connexins, were degraded at a rapid rate (Figure 2). Inhibition of
new protein synthesis with cycloheximide resulted in the
loss of all immunofluorescently detectable E186K Cx32 (Figure 8) as well as E208K (Figure 7) and R142W Cx32 (our
unpublished results) within a 6-h period, indicating that fast
turnover is a property of the total cellular pool of mutant
Cx32 and not just the fraction that incorporates [35S]methionine during a 30-min pulse. Second, ALLN and lactacystin
inhibited the degradation of all three mutants within the
early secretory pathway, implicating the proteasome in their
destruction. Third, the mutants were soluble in 4°C Triton
X-100 as detected by either immunoprecipitation after a 4-h
labeling (⬎twice the t1/2 of the protein) (Figure 3) or by
Western blotting (our unpublished results), in contrast to
certain abnormal proteins that form toxic aggregates (Graham et al., 1990; Skovronsky et al., 1998; Greenfield et al.,
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1999). Our findings in PC12 cells are consistant with the
observation (L. Bone, A. Messing, R. Balice-Gordon, K. Fischbeck, and S. Scherer, unpublished observation) that the ER
and Golgi compartments of Schwann cells of transgenic
mice expressing the R142W Cx32 mutant appear normal
instead of taking on the distended morphology characteristic of class II disorders and their murine models, including
Pelizaeus–Merzbacher disease (Gow and Lazzarini, 1996),
␣1-anti-trypsin deficiency (Carlson et al., 1989), and congenital hypothyroid goiter (Mayerhofer et al., 1988; Aridor and
Balch, 1999).
The absence of evidence of intracellular accumulation of
CMTX-linked Cx32 mutants does not, however, mandate
that they act as simple nulls. Several such mutants, including E186K and R142W Cx32, have been shown to inhibit the
function of coexpressed WT Cx32 in paired Xenopus oocytes
(Bruzzone et al., 1994), transfected tissue culture cells (Omori
et al., 1996), and/or (in the case of R142W Cx32) transgenic
mice (Scherer et al., 1999). Bruzzone et al. (1994) have demonstrated that E186K and R142W Cx32 also block the activity
of certain other, but not all, connexin family members. Because the Cx32 gene is subject to X inactivation (Scherer et
al., 1998), WT and mutant forms of Cx32 do not coexist
within the same cell in CMTX patients. Any physiologically
relevant interaction must therefore be between mutant Cx32
and a non-Cx32 connexin. Evidence for the existence of other
connexin species in myelinating Schwann cells has recently
been provided by Balice-Gordon et al. (1998), who demonstrated the continued presence of a radial pathway for the
diffusion of a gap junction tracer through the incisures of
Schmidt–Lanterman in cx32-null mice. Because of their dominant negative activity, it had been assumed that CMTXlinked Cx32 mutants co-oligomerize with wild-type connexins to form mixed connexons. We show here, however, that
the R142W and E186K Cx32 mutants are not capable of
assembling into connexons when expressed individually in
PC12 cells, raising the possibility that they act instead by
engaging wild-type connexins in some other type of complex formation or by outcompeting the normal protein for
binding to an as yet unknown limiting factor required for
gap junction assembly or trafficking. The gain-of-function
activity of the R142W and E186K Cx32 mutants is therefore
distinct from that of dominant nephrogenic diabetes insipidus-causing mutations of aquaporin-2, which is closely correlated with their ability to assemble into homo-oligomers in
the absence of the wild-type protein (Kamsteeg et al., 1999).
Investigation of the mechanism and potential physiological
significance of the dominant negative activity of R142W
Cx32 and other CMTX-linked mutants awaits the definitive
identification of the connexin species that coexist with Cx32
in myelinating Schwann cells.

Quality Control of Connexins in the Secretory
Pathway as Revealed by CMTX-linked
Cx32 Mutants
The selective recognition, retention, and degradation of incorrectly folded proteins in the secretory pathway are mediated by a variety of mechanisms that have been referred to
as the cell’s quality control system (Hammond and Helenius, 1995). The studies presented here indicate that there
are at least three quality control processes that prevent ab-

normal connexin molecules from traversing the secretory
pathway. The earliest quality control checkpoint we have
identified is in the ER, where all of the E208K mutant was
recognized as non-native and directed to rapid, proteasomemediated degradation. Under all conditions tested, E208K
Cx32 was detectable solely within the ER even if its turnover
was slowed using inhibitors of the proteasome. ER localization of this mutant therefore appears to be due to true
retention rather than to rapid degradation or to retrieval
from the intermediate compartment or Golgi complex. In
principle, ER retention could be due to one of three alternative processes (Kim and Arvan, 1998): 1) aggregation into
insoluble complexes too large to be incorporated into a
budding transport vesicle; 2) acquisition of an ER retention
determinant in an otherwise normally folded protein; or 3)
protein misfolding and consequent recognition by, and
binding to, an ER resident. Although the basis for the transport block of E208K Cx32 is not yet known, the Triton X-100
solubility of this mutant and its inability to assemble into a
connexon render the first two mechanisms unlikely and
suggest instead a conformational defect consistent with the
third possibility.
Some of the R142W and E186K Cx32 molecules were
competent to pass through the checkpoint in the ER and
entered the Golgi region. Because neither mutant assembles
into connexons, the criteria for ER exit, unlike those for other
multisubunit proteins (Hurtley and Helenius, 1989), cannot
involve either the current or future oligomerization state.
Remarkably, these two point mutants were then subjected to
different post-ER quality control processes that prevented
unassembled connexin monomers from reaching the cell
surface. R142W Cx32 that exited the ER was transported to,
and degraded within, the endosome–lysosome system. In
contrast, post-ER pools of E186K Cx32 could not be detected
in lysosomes but instead underwent retrograde transport
from the Golgi region to the ER and remained sensitive to
inhibitors of proteasomal degradation. Turnover of E186K
Cx32 is therefore distinct from that of a mutant form of
asialoglycoprotein receptor H1 subunit described by Wahlberg et al. (1995), which also exits the ER and is unaffected by
lysosomal inhibitors but does not appear to return to the ER
even after a 3.5-h chase with cycloheximide. Given its role in
the degradation of other proteins at the ER, it is possible that
the translocon mediates the dislocation of mutant connexins
from the membrane into the proteasome (Plemper and Wolf,
1999). Such a process would require E186K Cx32 molecules
to post-translationally reengage this channel after their return from post-ER compartments.
Degradation at the ER is also a property of wild-type
connexins. As determined by pulse– chase analysis, newly
synthesized WT Cx32 and Cx43 molecules continue to undergo rapid, proteasome inhibitor-sensitive turnover even if
their exit from the ER is blocked with BFA (Figure 6). In this
respect connexins resemble the CFTR, up to ⬃80% of which
is destroyed by proteasome-mediated degradation in a preGolgi compartment (Jensen et al., 1995; Ward et al., 1995).
Conformational maturation of the CFTR appears to be a
slow and inefficient event involving interactions between
domains in spatially distant regions of this polytopic membrane protein. Errors in this process are believed to result in
a large population of incompletely folded CFTR molecules
that are recognized by the ER degradation machinery
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(Zhang et al., 1998). Cysteine scanning mutagenesis has indicated that the tertiary structure of connexins may also be
unusually complex, with multiple transmembrane domains
contributing to the channel pore (Oh et al., 1997; Zhou et al.,
1997). One possibility is that folding of wild-type connexins
is slow relative to the rate of connexin degradation, resulting
in the turnover of a large fraction of newly synthesized
connexin molecules before they can achieve a conformation
permissive for transport to the cell surface. Although such
inefficiency would seem counterproductive, it would serve
to limit the number of properly folded and therefore potentially assembly competent connexin molecules in the early
secretory pathway under physiological levels of connexin
expression. This would reduce the possibility of premature
formation of gap junctional plaques within intracellular
membranes, as has been observed after high-level overexpression of exogenous Cx32 in baby hamster kidney transfectants (Kumar et al., 1995).
A common assay for assessing connexin function is the
formation of intercellular channels between paired Xenopus
oocytes injected with connexin-encoding cRNA. Bruzzone et
al. (1994) have studied both the E186K and the R142W
CMTX-linked Cx32 mutants in this system and found, as we
have in PC12 cells, that these mutants are inactive. Surprisingly, both mutants appeared to accumulate at oocyte interfaces in a manner immunohistochemically indistinguishable
from functional WT Cx32 and thus very different from the
intracellular localization pattern observed in PC12 transfectants or (in the case of R142W Cx32) transgenic mice (Scherer
et al., 1999). The basis for the apparent mislocalization of the
E186K and R142W Cx32 mutants in Xenopus oocytes is unknown. Unlike the ⌬F508 mutant of the CFTR (Denning et
al., 1992), the trafficking defects of the CMTX-linked Cx32
mutants examined cannot be corrected by incubating PC12
cells at the lower temperatures (ⱕ27°C) at which oocytes are
maintained (our unpublished results). The slower rate of
connexin degradation in oocytes relative to mammalian cells
(Zhou et al., 1999) is also unlikely to be a factor, in that
decreasing the rate of mutant Cx32 turnover in PC12 cells
with proteasome inhibitors did not induce cell surface localization. Transport to the plasma membrane after exogenous
expression in oocytes, but not in mammalian cells, has also
been described for some mutants of the aquaporin-2 water
channel (Tamarappoo and Verkman, 1998; Yang et al., 1999).
Although it is conceivable that oocytes are more permissive
than mammalian cells in allowing misfolded proteins to
traverse the secretory pathway, it is difficult to imagine how
they would avoid the toxic consequences of inappropriate
localization of nonfunctional or malfunctioning proteins. A
more likely explanation for the cell surface expression of the
E186K and R142W Cx32 mutants observed by Bruzzone et al.
(1994) is that oocytes have a normal quality control system
but that the capacity of this system is exceeded by the very
high expression levels routinely achieved after injection of
cRNA into these enormous cells. Leakage of mutant or otherwise improperly folded membrane proteins to the cell
surface after supraphysiological overexpression has previously been described even in mammalian cells (Maimone
and Merlie, 1993; Cheng et al., 1995). An alternative possibility arises from a study by Mulders et al. (1998) in which an
aquaporin-2 mutant that by immunofluorescence microscopy appeared to be efficiently transported to the cell surface
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when expressed in Xenopus oocytes was shown by electron
microscopy to instead be localized to Golgi stacks concentrated immediately beneath the oolemma. Lack of resolution
between the oolemma and Golgi is, however, unlikely to
account for the observations of Bruzzone et al. (1994), because intracellular retention would not be expected to lead
to the reported concentration of the E186K and R142W Cx32
mutants at regions of cell– cell contact.

Relevance to Other Connexin-related Disorders
Following the identification of Cx32 mutations in CMTX
patients, additional human diseases have been genetically
linked to members of the connexin family (Kelsell et al., 1997;
Richard et al., 1998; Shiels et al., 1998; Xia et al., 1998; Mackay
et al., 1999). In light of our current studies, it is particularly
intriguing that an R to W substitution in position 143 of
Cx26, which corresponds to R142 in Cx32, is associated with
nonsyndromic deafness (Brobby et al., 1998) and that an
E183K mutation in Cx31 (equivalent to E186K in Cx32) is
found in individuals with autosomal dominant hearing impairment (Xia et al., 1998). It is therefore anticipated that
some of the findings reported here will be applicable to
disease-causing mutations in other connexins.

ACKNOWLEDGMENTS
We are greatly indebted to Steven Scherer (University of Pennsylvania Medical Center, Philadelphia, PA) and Kurt Fischbeck (National Institutes of Health, Bethesda, MD) for use of the Cx32expressing PC12 cell lines. We thank E. Hertzberg, D. Goodenough,
K. Moreman, T. O’Hare (Oregon Health Sciences University, Portland, OR), and W. Gallin for providing antibodies and M. Bogyo
and D. Koop (Oregon Health Sciences University) for proteasome
inhibitors. We are also grateful to R. Ruch for the MH1C1 cell line.
This work was supported in part by a grant from the Muscular
Dystrophy Association to L.S.M.

REFERENCES
Anzini, P., Neuberg, D.H., Schachner, M., Nelles, E., Willecke, K.,
Zielasek, J., Toyka, K.V., Suter, U., and Martini, R. (1997). Structural
abnormalities and deficient maintenance of peripheral nerve myelin
in mice lacking the gap junction protein connexin 32. J. Neurosci. 17,
4545– 4551.
Aridor, M., and Balch, W.E. (1999). Integration of endoplasmic
reticulum signaling in health and disease. Nat. Med. 5, 745–751.
Balice-Gordon, R.J., Bone, L.J., and Scherer, S.S. (1998). Functional
gap junctions in the schwann cell myelin sheath. J. Cell Biol. 142,
1095–1104.
Beardslee, M.A., Laing, J.G., Beyer, E.C., and Saffitz, J.E. (1998).
Rapid turnover of connexin43 in the adult rat heart. Circ. Res. 83,
629 – 635.
Bergoffen, J., Scherer, S.S., Wang, S., Scott, M.O., Bone, L.J., Paul,
D.L., Chen, K., Lensch, M.W., Chance, P.F., and Fischbeck, K.H.
(1993). Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 262, 2039 –2042.
Bone, L.J., Deschenes, S.M., Balice-Gordon, R.J., Fischbeck, K.H.,
and Scherer, S.S. (1997). Connexin32 and X-linked Charcot-MarieTooth disease. Neurobiol. Dis. 4, 221–230.
Bonifacino, J.S., and Weissman, A.M. (1998). Ubiquitin and the
control of protein fate in the secretory and endocytic pathways.
Annu. Rev. Cell Dev. Biol. 14, 19 –57.

Molecular Biology of the Cell

Connexin32 in CMTX Disease
Brobby, G.W., Muller-Myhsok, B., and Horstmann, R.D. (1998).
Connexin 26 R143W mutation associated with recessive nonsyndromic sensorineural deafness in Africa (letter). N. Engl. J. Med. 338,
548 –550.
Brodsky, J.L., and McCracken, A.A. (1997). ER-associated and proteasome-mediated protein degradation: how two topologically restricted events came together. Trends Cell Biol. 7, 151–156.
Bruzzone, R., White, T.W., Scherer, S.S., Fischbeck, K.H., and Paul,
D.L. (1994). Null mutations of connexin32 in patients with X-linked
Charcot-Marie-Tooth disease. Neuron 13, 1253–1260.
Carlson, J.A., Rogers, B.B., Sifers, R.N., Finegold, M.J., Clift, S.M.,
DeMayo, F.J., Bullock, D.W., and Woo, S.L. (1989). Accumulation of
PiZ alpha 1-antitrypsin causes liver damage in transgenic mice.
J. Clin. Invest. 83, 1183–1190.
Cascio, M., Kumar, N.M., Safarik, R., and Gilula, N.B. (1995). Physical characterization of gap junction membrane connexons (hemichannels) isolated from rat liver. J. Biol. Chem. 270, 18643–18648.
Castro, C., Gomez-Hernandez, J.M., Silander, K., and Barrio, L.C.
(1999). Altered formation of hemichannels and gap junction channels caused by C-terminal connexin-32 mutations. J. Neurosci. 19,
3752–3760.
Cheng, S.H., Fang, S.L., Zabner, J., Marshall, J., Piraino, S., Schiavi,
S.C., Jefferson, D.M., Welsh, M.J., and Smith, A.E. (1995). Functional
activation of the cystic fibrosis trafficking mutant delta F508-CFTR
by overexpression. Am. J. Physiol. 268, L615–L624.
Cole, N.B., Sciaky, N., Marotta, A., Song, J., and LippincottSchwartz, J. (1996). Golgi dispersal during microtubule disruption:
regeneration of Golgi stacks at peripheral endoplasmic reticulum
exit sites. Mol. Biol. Cell 7, 631– 650.
Denning, G.M., Anderson, M.P., Amara, J.F., Marshall, J., Smith,
A.E., and Welsh, M.J. (1992). Processing of mutant cystic fibrosis
transmembrane conductance regulator is temperature-sensitive.
Nature 358, 761–764.
Deschenes, S.M., Walcott, J.L., Wexler, T.L., Scherer, S.S., and Fischbeck, K.H. (1997). Altered trafficking of mutant connexin32.
J. Neurosci. 17, 9077–9084.
D’Urso, D., Prior, R., Greiner-Petter, R., Gabreels-Festen, A.A., and
Muller, H.W. (1998). Overloaded endoplasmic reticulum-Golgi
compartments, a possible pathomechanism of peripheral neuropathies caused by mutations of the peripheral myelin protein PMP22.
J. Neurosci. 18, 731–740.
Fallon, R.F., and Goodenough, D.A. (1981). Five-hour half-life of
mouse liver gap-junction protein. J. Cell Biol. 90, 521–526.
Goodenough, D.A., Goliger, J.A., and Paul, D.L. (1996). Connexins,
connexons, and intercellular communication. Annu. Rev. Biochem.
65, 475–502.
Goodenough, D.A., Paul, D.L., and Jesaitis, L. (1988). Topological
distribution of two connexin32 antigenic sites in intact and split
rodent hepatocyte gap junctions. J. Cell Biol. 107, 1817–1824.
Gow, A., and Lazzarini, R.A. (1996). A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nat. Genet. 13,
422– 428.
Gow, A., Southwood, C.M., and Lazzarini, R.A. (1998). Disrupted
proteolipid protein trafficking results in oligodendrocyte apoptosis
in an animal model of Pelizaeus-Merzbacher disease. J. Cell Biol.
140, 925–934.
Graham, K.S., Le, A., and Sifers, R.N. (1990). Accumulation of the
insoluble PiZ variant of human alpha 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level
of grp78/BiP. J. Biol. Chem. 265, 20463–20468.
Greenfield, J.P., Tsai, J., Gouras, G.K., Hai, B., Thinakaran, G., Checler, F., Sisodia, S.S., Greengard, P., and Xu, H. (1999). Endoplasmic

reticulum and trans-Golgi network generate distinct populations of
Alzheimer beta-amyloid peptides. Proc. Natl. Acad. Sci. USA 96,
742–747.
Hammond, C., and Helenius, A. (1995). Quality control in the secretory pathway. Curr. Opin. Cell Biol. 7, 523–529.
Hertzberg, E.L. (1984). A detergent-independent procedure for the
isolation of gap junctions from rat liver. J. Biol. Chem. 259, 9936 –
9943.
Hsu, V.W., Yuan, L.C., Nuchtern, J.G., Lippincott-Schwartz, J.,
Hammerling, G.J., and Klausner, R.D. (1991). A recycling pathway
between the endoplasmic reticulum and the Golgi apparatus for
retention of unassembled MHC class I molecules. Nature 352, 441–
444.
Hurtley, S.M., and Helenius, A. (1989). Protein oligomerization in
the endoplasmic reticulum. Annu. Rev. Cell Biol. 5, 277–307.
Ionasescu, V., Ionasescu, R., and Searby, C. (1996). Correlation between connexin 32 gene mutations and clinical phenotype in Xlinked dominant Charcot-Marie-Tooth neuropathy. Am. J. Med.
Genet. 63, 486 – 491.
Jackson, M.R., Nilsson, T., and Peterson, P.A. (1993). Retrieval of
transmembrane proteins to the endoplasmic reticulum. J. Cell Biol.
121, 317–333.
Jensen, T.J., Loo, M.A., Pind, S., Williams, D.B., Goldberg, A.L., and
Riordan, J.R. (1995). Multiple proteolytic systems, including the
proteasome, contribute to CFTR processing. Cell 83, 129 –135.
Kamsteeg, E.J., Wormhoudt, T.A., Rijss, J.P., van Os, C.H., and
Deen, P.M. (1999). An impaired routing of wild-type aquaporin-2
after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. EMBO J. 18, 2394 –2400.
Kelsell, D.P., Dunlop, J., Stevens, H.P., Lench, N.J., Liang, J.N.,
Parry, G., Mueller, R.F., and Leigh, I.M. (1997). Connexin 26 mutations in hereditary non-syndromic sensorineural deafness Nature
387, 80 – 83.
Kim, P.S., and Arvan, P. (1998). Endocrinopathies in the family of
endoplasmic reticulum (ER) storage diseases: disorders of protein
trafficking and the role of ER molecular chaperones. Endocr. Rev. 19,
173–202.
Klausner, R.D., Donaldson, J.G., and Lippincott-Schwartz, J. (1992).
Brefeldin A: insights into the control of membrane traffic and organelle structure. J. Cell Biol. 116, 1071–1080.
Kumar, N.M., Friend, D.S., and Gilula, N.B. (1995). Synthesis and
assembly of human beta 1 gap junctions in BHK cells by DNA
transfection with the human beta 1 cDNA. J. Cell Sci. 108, 3725–
3734.
Laing, J.G., and Beyer, E.C. (1995). The gap junction protein connexin43 is degraded via the ubiquitin proteasome pathway. J. Biol.
Chem. 270, 26399 –26403.
Laing, J.G., Tadros, P.N., Westphale, E.M., and Beyer, E.C. (1997).
Degradation of connexin43 gap junctions involves both the proteasome and the lysosome. Exp. Cell Res. 236, 482– 492.
Larsen, W.J., and Tung, H.N. (1978). Origin and fate of cytoplasmic
gap junction vesicles in rabbit granulosa cells. Tissue Cell 10, 585–
598.
Le, A.C., and Musil, L.S. (1998). Normal differentiation of cultured
lens cells after inhibition of gap junction-mediated intercellular
communication. Dev. Biol. 204, 80 –96.
Lee, D.H., and Goldberg, A.L. (1998). Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397– 403.
Mackay, D., Ionides, A., Kibar, Z., Rouleau, G., Berry, V., Moore, A.,
Shiels, A., and Bhattacharya, S. (1999). Connexin46 mutations in

1945

J.K. VanSlyke et al
autosomal dominant congenital cataract. Am. J. Hum. Genet. 64,
1357–1364.
Maimone, M.M., and Merlie, J.P. (1993). Interaction of the 43 kd
postsynaptic protein with all subunits of the muscle nicotinic acetylcholine receptor. Neuron 11, 53– 66.
Matlin, K.S., and Simons, K. (1983). Reduced temperature prevents
transfer of a membrane glycoprotein to the cell surface but does not
prevent terminal glycosylation. Cell 34, 233–243.
Mayerhofer, A., Amador, A.G., Beamer, W.G., and Bartke, A. (1988).
Ultrastructural aspects of the goiter in cog/cog mice. J. Hered. 79,
200 –203.
Mege, R.M., Matsuzaki, F., Gallin, W.J., Goldberg, J.I., Cunningham,
B.A., and Edelman, G.M. (1988). Construction of epithelioid sheets
by transfection of mouse sarcoma cells with cDNAs for chicken cell
adhesion molecules. Proc. Natl. Acad. Sci. USA 85, 7274 –7278.
Mellman, I., Fuchs, R., and Helenius, A. (1986). Acidification of the
endocytic and exocytic pathways. Annu. Rev. Biochem. 55, 663–700.
Mulders, S.M., et al. (1998). An aquaporin-2 water channel mutant
which causes autosomal dominant nephrogenic diabetes insipidus
is retained in the Golgi complex. J. Clin Invest. 102, 57– 66.
Murakami, T., Garcia, C.A., Reiter, L.T., and Lupski, J.R. (1996).
Charcot-Marie-Tooth disease and related inherited neuropathies.
Medicine 75, 233–250.
Musil, L.S. (1994). Structure and assembly of gap junctions. In:
Molecular Mechanisms of Epithelial Cell Junctions: From Development to Disease, ed. S. Citi, Austin, TX: R.G. Landes, 173–194.
Musil, L.S., Cunningham, B.A., Edelman, G.M., and Goodenough,
D.A. (1990). Differential phosphorylation of the gap junction protein
connexin43 in junctional communication-competent and -deficient
cell lines. J. Cell Biol. 111, 2077–2088.
Musil, L.S., and Goodenough, D.A. (1991). Biochemical analysis of
connexin43 intracellular transport, phosphorylation, and assembly
into gap junctional plaques. J. Cell Biol. 115, 1357–1374.
Musil, L.S., and Goodenough, D.A. (1993). Multisubunit assembly of
an integral plasma membrane channel protein, gap junction connexin43, occurs after exit from the ER. Cell 74, 1065–1077.
Oh, S., Ri, Y., Bennett, M.V., Trexler, E.B., Verselis, V.K., and Bargiello, T.A. (1997). Changes in permeability caused by connexin 32
mutations underlie X-linked Charcot-Marie-Tooth disease. Neuron
19, 927–938.

Sadeghi, H.M., Innamorati, G., and Birnbaumer, M. (1997). An
X-linked NDI mutation reveals a requirement for cell surface V2R
expression. Mol. Endocrinol. 11, 706 –713.
Scherer, S.S., Bone, L.J., Deschenes, S.M., Abel, A., Balice-Gordon,
R.J., and Fischbeck, K.H. (1999). The role of the gap junction protein
connexin32 in the pathogenesis of X-linked Charcot-Marie-Tooth
disease. Novartis Found. Symp. 219, 175–185.
Scherer, S.S., Deschenes, S.M., Xu, Y.T., Grinspan, J.B., Fischbeck,
K.H., and Paul, D.L. (1995). Connexin32 is a myelin-related protein
in the PNS and CNS. J. Neurosci. 15, 8281– 8294.
Scherer, S.S., Xu, Y.T., Nelles, E., Fischbeck, K., Willecke, K., and
Bone, L.J. (1998). Connexin32-null mice develop demyelinating peripheral neuropathy. Glia 24, 8 –20.
Seglen, P.O. (1983). Inhibitors of lysosomal function. Methods Enzymol. 96, 737–764.
Shiels, A., Mackay, D., Ionides, A., Berry, V., Moore, A., and Bhattacharya, S. (1998). A missense mutation in the human connexin50
gene (GJA8) underlies autosomal dominant “zonular pulverulent”
cataract, on chromosome 1q. Am. J. Hum. Genet. 62, 526 –532.
Skovronsky, D.M., Doms, R.W., and Lee, V.M. (1998). Detection of a
novel intraneuronal pool of insoluble amyloid beta protein that
accumulates with time in culture. J. Cell Biol. 141, 1031–1039.
Stevens, T.H., and Forgac, M. (1997). Structure, function and regulation of the vacuolar (H⫹)-ATPase. Annu. Rev. Cell Dev. Biol. 13,
779 – 808.
Tamarappoo, B.K., and Verkman, A.S. (1998). Defective aquaporin-2
trafficking in nephrogenic diabetes insipidus and correction by
chemical chaperones. J. Clin. Invest. 101, 2257–2267.
VanSlyke, J.K., and Musil, L.S. (2000). Analysis of connexin intracellular transport and assembly. Methods 20, 156 –164.
Wahlberg, J.M., Geffen, I., Reymond, F., Simmen, T., and Spiess, M.
(1995). trans-Golgi retention of a plasma membrane protein: mutations in the cytoplasmic domain of the asialoglycoprotein receptor
subunit H1 result in trans-Golgi retention. J. Cell Biol. 130, 285–297.
Ward, C.L., Omura, S., and Kopito, R.R. (1995). Degradation of
CFTR by the ubiquitin-proteasome pathway. Cell 83, 121–127.
Xia, J.H., et al. (1998). Mutations in the gene encoding gap junction
protein beta-3 associated with autosomal dominant hearing impairment. Nat. Genet. 20, 370 –373.

Omori, Y., Mesnil, M., and Yamasaki, H. (1996). Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects. Mol. Biol. Cell 7,
907–916.

Yang, B., Ma, T., Xu, Z., and Verkman, A.S. (1999). cDNA and
genomic cloning of mouse aquaporin-2: functional analysis of an
orthologous mutant causing nephrogenic diabetes insipidus.
Genomics 57, 79 – 83.

Plemper, R.K., and Wolf, D.H. (1999). Retrograde protein translocation: ERADication of secretory proteins in health and disease.
Trends Biochem. Sci. 24, 266 –270.

Yoshimura, T., Satake, M., Ohnishi, A., Tsutsumi, Y., and Fujikura,
Y. (1998). Mutations of connexin32 in Charcot-Marie-Tooth disease
type X interfere with cell-to-cell communication but not cell proliferation and myelin-specific gene expression. J. Neurosci. Res. 51,
154 –161.

Ren, P., de Feijter, A.W., Paul, D.L., and Ruch, R.J. (1994). Enhancement of liver cell gap junction protein expression by glucocorticoids.
Carcinogenesis 15, 1807–1813.
Richard, G., Smith, L.E., Bailey, R.A., Itin, P., Hohl, D., Epstein, E.H.,
Jr., DiGiovanna, J.J., Compton, J.G., and Bale, S.J. (1998). Mutations
in the human connexin gene GJB3 cause erythrokeratodermia variabilis. Nat. Genet. 20, 366 –369.
Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L.,
Hwang, D., and Goldberg, A.L. (1994). Inhibitors of the proteasome
block the degradation of most cell proteins and the generation of
peptides presented on MHC class I molexules. Cell 78, 761–771.

1946

Zhang, F., Kartner, N., and Lukacs, G.L. (1998). Limited proteolysis
as a probe for arrested conformational maturation of delta F508
CFTR. Nat. Struct. Biol. 5, 180 –183.
Zhou, L., Kasperek, E.M., and Nicholson, B.J. (1999). Dissection of
the molecular basis of pp60(v-src) induced gating of connexin 43
gap junction channels. J. Cell Biol. 144, 1033–1045.
Zhou, X.W., Pfahnl, A., Werner, R., Hudder, A., Llanes, A., Luebke,
A., and Dahl, G. (1997). Identification of a pore lining segment in
gap junction hemichannels. Biophys. J. 72, 1946 –1953.

Molecular Biology of the Cell

